[Antioxidant activity of mildronate and L-carnitine in the treatment of patients with cerebrovascular diseases].
The antioxidant properties of mildronate and a structurally close compound L-carnitine were studied under clinical conditions during the therapy of patients with acute lacunar stroke and discirculatory encephalopathy (DEP) on the background of diabetes mellitus, respectively. Administered in addition to the base course of therapy, both mildronate (in a daily dose of 500 mg) and L-carnitine (2 mg) increased the resistance of blood serum lipoproteins with respect to peroxidation. It was concluded that the drugs possess antioxidant activity and offer protection against lipid peroxidation. L-carnitine acute produced a significant hypoglycemic action and made possible an almost twofold (42%) decrease in the dose of hypoglycemic drugs. The administration of L-carnitine also improved both abstract and concrete thinking and memory function in DEP patients. The results allowed mildronate and L-carnitine to be included in the complex therapy of patients with cerebrovascular diseases.
Suslina
Z A
ZA
Department of Neurochemistry, Institute of Neurology, Russian Academy of Medical Sciences, Volokolamskoe sh. 80, Moscow, 123367 Russia.
Fedorova
T N
TN
Maksimova
M Iu
MIu
Kim
E K
EK
D000208:Acute Disease; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002331:Carnitine / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy*; D048909:Diabetes Complications; D006801:Humans; D008763:Methylhydrazines / Q000627:therapeutic use*; D020521:Stroke / Q000150:complications / Q000188:drug therapy
D000975:Antioxidants; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate; D002331:Carnitine